The Efficacy Of Adjunctive Garcinia Mangostana Linn. Pericarp For Bipolar Depression: A 24-week Double-blind, Randomized, Placebo-controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$1,227,272.00
Summary
Bipolar disorder, especially during episodes of depression, can be highly debilitating. There is scientific evidence now directing research towards new targets to produce new therapies for bipolar depression. The current study aims to utilise an entirely new agent made from the husk of the mangosteen fruit (mangosteen pericarp). Mangosteen pericarp has properties that we believe will assist in reducing symptoms for those with bipolar depression, when taken in addition to usual treatment.
Optimizing The Management Of Osteoarthritis Through Research And Innovation
Funder
National Health and Medical Research Council
Funding Amount
$2,889,164.00
Summary
I will test new treatments aimed at slowing disease progression and reducing pain in osteoarthritis (OA) by targeting specific disease pathways (metabolic factors and inflammation). I will undertake work examining the causes of hip OA where little is known. All required methodologies and resources to undertake this work are available and the trials underpinned by strong scientific rationale. This research program has high potential for translation and for reducing the burden and cost of OA.
The Biology Of Cervical Disc Damage And Stem Cell Applications For Repair.
Funder
National Health and Medical Research Council
Funding Amount
$82,554.00
Summary
Disruption of the cervical disc by degeneration or trauma is common and therefore a major public health issue causing significant pain and disability in the community. The understanding of the changes that occur in disc degeneration would be greatly enhanced by comparison with changes that occur in normal discs and in discs recently disrupted by trauma. Potential applications of adult stem cells or their derivatives for disc repair and regeneration will be explored.
More Effective Therapeutic Targeting Of High Risk Childhood Cancer: Neuroblastoma As A Model
Funder
National Health and Medical Research Council
Funding Amount
$6,601,220.00
Summary
Cancer is the commonest cause of death from disease in Australian children. Childhood neuroblastoma is a particularly aggressive cancer, for which new treatment approaches are urgently needed. The team aims to discover better safer therapies for children with this cancer, conducting clinical trials using new drugs and novel drug combinations. We will also investigate novel ways of targeting neuroblastoma cells and identify therapeutic targets in neuroblastoma-initiating cells.
Integrated Exploration Of Novel Therapies For Depression
Funder
National Health and Medical Research Council
Funding Amount
$476,728.00
Summary
There is a clear need for new therapies for psychiatric illnesses, particularly depression. Current antidepressant therapy is useful but leaves many with a shortfall to functional recovery. My research program investigates new therapies for depression, in the context of the biological understanding of depression.
Optimising Targeted Polyamine Depletion For Treatment Of Childhood Neuroblastoma And Brain Tumours
Funder
National Health and Medical Research Council
Funding Amount
$928,152.00
Summary
Paediatric neuroblastoma and brain tumours, which often have dismal outcomes despite intensive therapy, have high levels of polyamines, which are essential for cell growth. We have shown that depleting polyamines, combined with chemotherapy, represents a highly promising therapy for neuroblastoma. We will make this exciting new treatment approach even more effective by comparing three ways of enhancing polyamine depletion, as a precursor to future neuroblastoma and brain tumour clinical trials.